MA55316A - Polythérapies anticancéreuses comprenant des agents de blocage de ctla-4 et pd-1 - Google Patents

Polythérapies anticancéreuses comprenant des agents de blocage de ctla-4 et pd-1

Info

Publication number
MA55316A
MA55316A MA055316A MA55316A MA55316A MA 55316 A MA55316 A MA 55316A MA 055316 A MA055316 A MA 055316A MA 55316 A MA55316 A MA 55316A MA 55316 A MA55316 A MA 55316A
Authority
MA
Morocco
Prior art keywords
blocking agents
therapies including
including ctla
cancer multi
cancer
Prior art date
Application number
MA055316A
Other languages
English (en)
Inventor
Lakshmanan Annamalai
David Bauche
Edward Bowman
Alissa Chackerian
Jeffery Grein
Drake Laface
Smita Mauze
Juha Punnonen
Anandi Sawant
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA55316A publication Critical patent/MA55316A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA055316A 2019-03-13 2020-03-10 Polythérapies anticancéreuses comprenant des agents de blocage de ctla-4 et pd-1 MA55316A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962817749P 2019-03-13 2019-03-13

Publications (1)

Publication Number Publication Date
MA55316A true MA55316A (fr) 2022-01-19

Family

ID=72426465

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055316A MA55316A (fr) 2019-03-13 2020-03-10 Polythérapies anticancéreuses comprenant des agents de blocage de ctla-4 et pd-1

Country Status (11)

Country Link
US (1) US20220411507A1 (fr)
EP (1) EP3937979A4 (fr)
JP (1) JP2022525071A (fr)
KR (1) KR20210141539A (fr)
CN (1) CN113631189A (fr)
AU (1) AU2020234785A1 (fr)
BR (1) BR112021017892A8 (fr)
CA (1) CA3132198A1 (fr)
MA (1) MA55316A (fr)
MX (1) MX2021010997A (fr)
WO (1) WO2020185722A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20220530A (es) 2020-04-22 2022-12-15 Merck Sharp & Dohme Llc CONJUGADOS DE INTERLEUCINA 2 HUMANA SESGADOS AL DÍMERO DEL RECEPTOR DE INTERLEUCINA 2 ß¿c Y CONJUGADOS CON UN POLÍMERO HIDROSOLUBLE NO PEPTÍDICO.
WO2022161454A1 (fr) * 2021-01-29 2022-08-04 明慧医药（杭州）有限公司 Protéine de liaison à l'antigène et son utilisation
KR20230171456A (ko) * 2021-04-14 2023-12-20 아케소 파마슈티컬스, 인코포레이티드 항-종양 치료에서의 항체의 용도
WO2022222961A1 (fr) * 2021-04-21 2022-10-27 和铂医药(上海)有限责任公司 Anticorps liant ctla-4 et son utilisation
KR20230110141A (ko) 2022-01-14 2023-07-21 영남대학교 산학협력단 PD-L1 단백질에 특이적으로 결합하는 Fab 단편 및 이의 용도
WO2023217987A1 (fr) * 2022-05-12 2023-11-16 BioNTech SE Anticorps monoclonaux dirigés contre la protéine de mort programmée 1 et leur utilisation en médecine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060235208A1 (en) * 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
KR20230144099A (ko) * 2014-05-15 2023-10-13 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항암제의 조합물을 사용한 폐암의 치료
JP2020512354A (ja) * 2017-03-31 2020-04-23 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｐｄ−１のアンタゴニストと抗ｃｔｌａ４抗体との組み合わせでがんを処置するための組成物および方法

Also Published As

Publication number Publication date
JP2022525071A (ja) 2022-05-11
AU2020234785A1 (en) 2021-08-19
CN113631189A (zh) 2021-11-09
WO2020185722A3 (fr) 2020-11-12
BR112021017892A2 (fr) 2021-12-07
BR112021017892A8 (pt) 2023-01-31
WO2020185722A2 (fr) 2020-09-17
KR20210141539A (ko) 2021-11-23
EP3937979A4 (fr) 2023-03-08
US20220411507A1 (en) 2022-12-29
EP3937979A2 (fr) 2022-01-19
MX2021010997A (es) 2021-10-01
CA3132198A1 (fr) 2020-09-17

Similar Documents

Publication Publication Date Title
MA55316A (fr) Polythérapies anticancéreuses comprenant des agents de blocage de ctla-4 et pd-1
DK4015003T5 (da) Forbedret antistof-oligonukleotid-konjugat
MA51447A (fr) Conjugué anticorps monoclonal-médicament dirigé contre bcma
MA50147A (fr) Inhibiteurs de pd-1/pd-l1
IL262892A (en) Anti-pd-1 and anti-lag3 antibodies for cancer therapy
EP3664829A4 (fr) Agents de liaison à pd-1 et pd-l1
MA55565A (fr) Agents de dégradation de stat et leurs utilisations
MA49042A (fr) Polythérapies ciblant pd-1, tim-3 et lag-3
IL268102A (en) Anti-GPR 20 antibody and anti-GPR 20 antibody-drug conjugate
BR112017011538A2 (pt) combinação de anticorpos anti-cs1 e anti-pd1 para tratar câncer (mieloma)
DK3672405T3 (da) Antimikrobielle gasfrigivende midler samt systemer og fremgangsmåder til anvendelse deraf
ES1275799Y (es) Acondicionador de suelo
DK3610712T3 (da) Landbrugstværbearbejdningsindretning
TWI799438B (zh) 半星芒體衍生物及此等之抗體藥物複合體
IL282273A (en) History of Urea for the treatment and prevention of cancer
DK3547330T3 (da) Strålebeskyttelsesbeklædningssystem
IL277979A (en) Combination comprising hdac inhibitor, lag-3 inhibitor and a pd-1 inhibitor or pd-l1 inhibitor for cancer treatment
IT201900020514A1 (it) Dispositivo di irrigazione e/o fertirrigazione
EP3691694A4 (fr) Anticorps monoclonaux d'adn ciblant le ctla-4 pour le traitement et la prévention du cancer
DE112020003310A5 (de) Einkaufs- und bezahlsystem
FR3043490B1 (fr) Paravent de radioprotection
ES2981743T3 (es) Protección de entrada
ES1290154Y (es) Rodillo agricola desgarrador
TH191163S (th) เครื่องหว่านเมล็ดและปุ๋ย
IT201900021516A1 (it) Monile Perfezionato.